Novel Thiosemicarbazones Sensitize Pediatric Solid Tumor Cell-Types to Conventional Chemotherapeutics through Multiple Molecular Mechanisms

Overcoming tamoxifen resistance in oestrogen receptor‐positive breast cancer using the novel thiosemicarbazone anti‐cancer agent, DpC

(2020) Sundus N. Maqbool et al.   BRITISH JOURNAL OF PHARMACOLOGY

Unique targeting of androgen‐dependent and ‐independent AR signaling in prostate cancer to overcome androgen resistance

(2020) Syer C. Lim et al.   FASEB JOURNAL

The metastasis suppressor NDRG1 down-regulates the epidermal growth factor receptor via a lysosomal mechanism by up-regulating mitogen-inducible gene 6

(2019) Sharleen V. Menezes et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Exploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents

(2019) Angelica M. Merlot et al.   CURRENT MEDICINAL CHEMISTRY

Two mechanisms involving the autophagic and proteasomal pathways process the metastasis suppressor protein, N-myc downstream regulated gene 1

(2019) Sumit Sahni et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Pharmacological targeting and the diverse functions of the metastasis suppressor, NDRG1, in cancer

(2019) Kyung Chan Park et al.   FREE RADICAL BIOLOGY AND MEDICINE

Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding.

(2019) Kyung Chan Park et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Identification of differential phosphorylation and sub-cellular localization of the metastasis suppressor, NDRG1

(2018) Kyung Chan Park et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

In vitro assessment of the role of DpC in the treatment of head and neck squamous cell carcinoma

(2018) Ye‑Xing Xu et al.   Oncology Letters

The Metastasis Suppressor, NDRG1, Attenuates Oncogenic TGF-β and NF-ĸB Signaling to Enhance Membrane E-Cadherin Expression in Pancreatic Cancer Cells

(2018) Sharleen V Menezes et al.   CARCINOGENESIS

Cancer treatment and survivorship statistics, 2016

(2016) Kimberly D. Miller et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms

(2016) Zhu-Ling Guo et al.   Journal of Hematology & Oncology

Zinc(II)–Thiosemicarbazone Complexes Are Localized to the Lysosomal Compartment Where They Transmetallate with Copper Ions to Induce Cytotoxicity

(2016) Alexandra E. Stacy et al.   JOURNAL OF MEDICINAL CHEMISTRY

A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC

(2016) Nicole A Seebacher et al.   Cell Death & Disease

Di-2-pyridylketone 4,4-Dimethyl-3-thiosemicarbazone (Dp44mT) Overcomes Multidrug Resistance by a Novel Mechanism Involving the Hijacking of Lysosomal P-Glycoprotein (Pgp)

(2015) Patric J. Jansson et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways

(2015) Zaklina Kovacevic et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

SDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery

(2015) Neetu Saxena et al.   JNCI-Journal of the National Cancer Institute

Overexpression of N-myc downstream-regulated gene 1 inhibits human glioma proliferation and invasion via phosphoinositide 3-kinase/AKT pathways

(2015) WEI MA et al.   Molecular Medicine Reports

The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the “Triad of Death” in cancer by Di-2-pyridylketone thiosemicarbazones

(2015) Patric J. Jansson et al.   PHARMACOLOGICAL RESEARCH

Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance

(2015) Malin Wickström et al.   Nature Communications

SDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery

(2015) Neetu Saxena et al.   JNCI-Journal of the National Cancer Institute

The Anticancer Agent Di-2-pyridylketone 4,4-Dimethyl-3-thiosemicarbazone (Dp44mT) Overcomes Prosurvival Autophagy by Two Mechanisms

(2014) Elaine Gutierrez et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of  -catenin through mechanisms involving FRAT1 and PAK4

(2014) R. Jin et al.   JOURNAL OF CELL SCIENCE

Quantitative Analysis of the Anti-Proliferative Activity of Combinations of Selected Iron-Chelating Agents and Clinically Used Anti-Neoplastic Drugs

(2014) Eliska Potuckova et al.   PLoS One

LOX/COX inhibitors enhance the antineoplastic effects of all-trans retinoic acid in osteosarcoma cell lines

(2014) Miroslava Krzyzankova et al.   TUMOR BIOLOGY

Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells

(2013) K M Dixon et al.   BRITISH JOURNAL OF CANCER

Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors

(2013) J. Sun et al.   CARCINOGENESIS

The Iron-Regulated Metastasis Suppressor NDRG1 Targets NEDD4L, PTEN, and SMAD4 and Inhibits the PI3K and Ras Signaling Pathways

(2012) Zaklina Kovacevic et al.   ANTIOXIDANTS & REDOX SIGNALING

The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα

(2012) Jack C. Yalowich et al.   BIOCHEMICAL PHARMACOLOGY

N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasis

(2012) Wen Liu et al.   EMBO Molecular Medicine

Transcriptional and translational regulation of COX-2 expression by cadmium in C6 glioma cells

(2012) YU-KYOUNG PARK et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

The Iron Chelators Dp44mT and DFO Inhibit TGF-β-induced Epithelial-Mesenchymal Transition via Up-Regulation of N-Myc Downstream-regulated Gene 1 (NDRG1)

(2012) Zhiqiang Chen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Novel Second-Generation Di-2-Pyridylketone Thiosemicarbazones Show Synergism with Standard Chemotherapeutics and Demonstrate Potent Activity against Lung Cancer Xenografts after Oral and Intravenous Administration in Vivo

(2012) David B. Lovejoy et al.   JOURNAL OF MEDICINAL CHEMISTRY

Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells

(2012) Caroline Happold et al.   JOURNAL OF NEUROCHEMISTRY

Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience

(2012) D. Zapletalova et al.   ONCOLOGY

Targeting apoptosis pathways by Celecoxib in cancer

(2011) Verena Jendrossek   CANCER LETTERS

Antitumor Activity of Metal-Chelating Compound Dp44mT Is Mediated by Formation of a Redox-Active Copper Complex That Accumulates in Lysosomes

(2011) D. B. Lovejoy et al.   CANCER RESEARCH

The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms

(2011) Zaklina Kovacevic et al.   CARCINOGENESIS

Redox control of iron regulatory protein 2 stability

(2011) Anja Hausmann et al.   FEBS LETTERS

Targeting DNA repair and the cell cycle in glioblastoma

(2011) Brian M. Alexander et al.   JOURNAL OF NEURO-ONCOLOGY

Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc Down-Stream Regulated Gene 1: A New Strategy for the Treatment of Pancreatic Cancer

(2011) Z. Kovacevic et al.   MOLECULAR PHARMACOLOGY

Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on Celecoxib-induced apoptosis

(2009) Justine Rudner et al.   BIOCHEMICAL PHARMACOLOGY

The Iron Chelator Dp44mT Causes DNA Damage and Selective Inhibition of Topoisomerase II  in Breast Cancer Cells

(2009) V. A. Rao et al.   CANCER RESEARCH

MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance

(2009) S. Yip et al.   CLINICAL CANCER RESEARCH